Atrial Fibrillation Clinical Trials in Charlottesville, Virginia

6 studies are recruiting for atrial fibrillation in Charlottesville, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Fourth Left Atrial Appendage Occlusion Study

   LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Rector and Visitors of the University of Virginia, Charlottesville, Virginia

   Locations

   150 in total

   Run by

   Hamilton Health Sciences Corporation

   See if you can join NCT05963698 on ClinicalTrials.gov

2. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   University of Virginia, Charlottesville, Virginia

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

3. PULSED AF Post-Approval Study

   PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Virginia Medical Center, Charlottesville, Virginia

   Locations

   23 in total

   Run by

   Medtronic Cardiac Ablation Solutions

   See if you can join NCT06578104 on ClinicalTrials.gov

4. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Virginia Health System, Charlottesville, Virginia

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

5. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UVA Medical Center, Charlottesville, Virginia

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov

6. CardioFocus HeartLight Post-Approval Study

   This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University Of Virginia Health System, Charlottesville, Virginia

   Locations

   4 in total

   Run by

   CardioFocus

   See if you can join NCT03168659 on ClinicalTrials.gov